Sanjay Popat

35PUBLICATIONS
146CO-AUTHORS
Memory and attentionMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Environmental and resources law not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Jul 10, 2026
Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

|May 08, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

|May 05, 2026
Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.

|Feb 24, 2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.

Arnaud Scherpereel, Paul Baas, Anna K Nowak

|Feb 04, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.

Benjamin Besse, Jessica J Lin, Lyudmila Bazhenova

|Jan 14, 2026
Retraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy.

Kevin W Ng, Jesse Boumelha, Katey S S Enfield

Pageof 6

Frequent Collaborators

5 joint publications

Charles Swanton

3 joint publications

Gary Middleton

3 joint publications

Allan Hackshaw

3 joint publications

Benjamin Besse